Skip to content

Intranasal ketamine shows rapid effects in depression study

The Brown University Psychopharmacology Update March 1, 2015 DOI: 10.1002/pu.30029 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population Patients with treatment-resistant depression
Intervention Intranasal ketamine
Dose 50 mg
Topics Depression Esketamine Ketamine
Key findings A single 50-mg intranasal dose of ketamine was associated with rapid antidepressant response in patients with treatment-resistant depression, with a significant effect seen 40 minutes after administration.

Abstract

A new randomized, double‐blind crossover study has found that a single 50‐mg dose of intranasal ketamine was associated with rapid antidepressant response in patients with treatment‐resistant depression, with a significant effect seen 40 minutes after administration.

Comparable studies

Other randomized controlled trials on ketamine for depression, most cited first.

Study Year Design Participants
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial Patients with treatment-resistant major depression experiencing a major depressive episode 2013 Randomized controlled trial n = 73
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Adults with moderate to severe nonpsychotic depression and a history of nonresponse to... 2019 Phase 3, double-blind, active-controlled, multicenter randomized controlled trial n = 227
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression Adults with treatment-resistant depression who achieved stable remission or stable... 2019 Phase 3, multicenter, double-blind, randomized withdrawal study n = 297
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression Adults with DSM-IV-TR diagnosis of major depressive disorder and history of inadequate... 2017 Phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study n = 67
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Depressed patients at imminent risk for suicide 2018 Randomized controlled trial n = 68

Related reading

Explore topics

Depression Esketamine Ketamine

By condition and practice

Ketamine for depression